Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL 3
2023-506130-67-00Phase 3Completed
- Sponsor
- QED Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in achondroplasia (ACH) comparing Infigratinib with Placebo (2 arms). Primary endpoint: Change from baseline in annualized height velocity compared with placebo. Started Mar 2024; status: completed.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2023-506130-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506130-67-00.